- Home
- HAVA vs DTIL Comparison
HAVA vs DTIL Comparison
Compare HAVA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$7.02
Company Overview
Basic Information| Metric | HAVA | DTIL |
|---|---|---|
| Founded | 2024 | 2006 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 214.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HAVA | DTIL |
|---|---|---|
| Price | $10.17 | $7.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 23.1K | ★ 456.1K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $3.53 |
| 52 Week High | $10.15 | $9.62 |
Technical Indicators
Market Signals| Indicator | HAVA | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 40.29 |
| Support Level | $9.98 | $6.30 |
| Resistance Level | N/A | $7.96 |
| Average True Range (ATR) | 0.00 | 0.50 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 100.00 | 13.72 |
Price Performance
Historical Comparison HAVA
DTIL
About HAVA Harvard Ave Acquisition Corporation Class A Ordinary Share
Harvard Ave Acquisition Corp is a blank check company.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).